Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of Gadolinium in Individuals with Reduced Kidney Function.

× No keyword cloud information.

9 in total

1. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications.

Authors: Phillip H Kuo
Journal: AJR Am J Roentgenol Date: 2008-12 Impact factor: 3.959

2. Gadolinium Retention After Contrast-Enhanced MRI.

Authors: Deborah Levine; Robert J McDonald; Herbert Y Kressel
Journal: JAMA Date: 2018-11-13 Impact factor: 56.272

3. Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease-Is Zero Good Enough?

Authors: Saugar Maripuri; Kirsten L Johansen
Journal: JAMA Intern Med Date: 2019-12-09 Impact factor: 21.873

4. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Authors: Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport
Journal: JAMA Intern Med Date: 2020-02-01 Impact factor: 21.873

5. Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors.

Authors: Catherine Do; Bridget Ford; Doug Yoon Lee; Chunyan Tan; Patricia Escobar; Brent Wagner
Journal: Toxicol Appl Pharmacol Date: 2019-05-10 Impact factor: 4.219

6. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.

Authors: Nicola Schieda; Pejman Jabehdar Maralani; Casey Hurrell; Anne K Tsampalieros; Swapnil Hiremath
Journal: Can Assoc Radiol J Date: 2019-06-27 Impact factor: 2.248

Use of Gadolinium in Individuals with Reduced Kidney Function.

1. NSF-active and NSF-inert species of gadolinium: mechanistic and clinical implications.

2. Gadolinium Retention After Contrast-Enhanced MRI.

3. Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease-Is Zero Good Enough?

4. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

5. Gadolinium-based contrast agents: Stimulators of myeloid-induced renal fibrosis and major metabolic disruptors.

6. Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.

7. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.

8. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis.

9. A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.